Drug Search Results
More Filters [+]

Indisulam

Alternative Names: indisulam, e7070
Latest Update: 2024-04-19
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CDK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Indisulam

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Colorectal Cancer|Melanoma|Breast Cancer|Gastrointestinal Cancer|Adenocarcinoma|Renal Cell Carcinoma|Myelodysplastic Syndrome|Preleukemia

Phase 1: Oncology Solid Tumor Unspecified|Gastrointestinal Cancer|Pancreatic Cancer|Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCI-2012-02065

P2

Completed

Myelodysplastic Syndrome|Preleukemia

2017-06-07

E7070-A001-106

P1

Completed

Gastrointestinal Cancer|Lung Cancer|Pancreatic Cancer

2013-03-01

39%

E7070-J081-217

P2

Terminated

Gastrointestinal Cancer

2006-07-01

2004-002597-33

P2

Completed

Colorectal Cancer

2006-01-10

Recent News Events